Blood pressure drugs Benicar, Benicar HCT, Azor and Tribenzor have been linked to a gastrointestinal disorder known as sprue-like enteropathy. With thousands of personal injury and wrongful death lawsuits already filed, drug company Daiichi Sankyo has offered $300 million to settle pending and unfiled claims.
While this litigation is currently closed, learn more about a Cuisinart pressure cooker class action from our team of attorneys.
Did you notice a TV commercial about the recent Benicar settlement?
Many law firms have begun to run ads on local stations, notifying hypertension patients and families that Daiichi Sankyo, the Japanese pharmaceutical company behind Benicar, has settled nearly 2,300 personal injury lawsuits for $300 million. The settlement, announced on August 1, 2017, is broad and comprehensive. As written, the agreement offers financial compensation to patients who took Benicar, Benicar HCT, Azor and / or Tribenzor and developed a range of gastrointestinal side effects.
While the attorneys at The Product Lawyers don’t produce TV commercials, our lawyers have proven an invaluable resource to many patients and families looking for help in the wake of Benicar-linked injuries.
Our experienced product liability lawyers are now offering free consultations to all interested parties. Hundreds of injured patients may still be able to file claims against the Benicar settlement fund, but there is a strict time limit. The fund will close to new claimants on August 23, 2017 at 11:59 pm E.T. This deadline applies both to personal injury lawsuits, filed by living patients, and wrongful death lawsuits brought by families who lost loved ones to alleged Benicar side effects.
The commercial you saw may have mentioned a medical condition called celiac disease. Celiac disease, or “sprue,” is an autoimmune disorder triggered by exposure to the wheat protein gluten.
Sprue often causes severe gastrointestinal symptoms, MedlinePlus reports. Patients can develop chronic diarrhea, nausea and vomiting, which can lead in turn to dehydration. Meanwhile, the intestines find it difficult to to absorb nutrients, resulting in malnutrition and undesired weight loss.
This same set of intestinal symptoms have been affecting patients who take drugs based on olmesartan medoxomil, a chemical found in Benicar, Benicar HCT, Azor and Tribenzor. Despite the similarity in symptoms, most olmesartan patients have not been diagnosed with celiac disease (sprue). Instead, they’ve been diagnosed with sprue-like enteropathy (“enteropathy” is simply a generic term for gastrointestinal conditions).
Settlement awards are not limited to patients who were diagnosed with sprue-like enteropathy. While patients with confirmed diagnoses are likely to receive the highest awards, financial compensation is also available to people who can present evidence that they experienced GI symptoms while taking an olmesartan product or that an olmesartan product aggravated pre-existing intestinal problems. People diagnosed with celiac disease may also be eligible.
Crucially, the fund isn’t just for patients and families who have already filed lawsuits. Individuals who have yet to come forward may still be able to pursue a claim, but there’s a strict deadline.
On Wednesday, August 23, 2017 at 11:59 pm E.T., the Benicar settlement program will stop accepting new claims. Time is running out. To secure compensation, claimants are required to hire legal counsel and submit their documentation to the program’s Claims Administrator by August 23.
Do not hesitate and miss out on this opportunity. Contact The Product Lawyers today for a free consultation. You can learn more about settlement eligibility, the filing process and what to expect – at no charge and no obligation. Even better, our experienced product liability lawyers work on a contingency-fee basis. That means you owe us nothing until we secure compensation in your claim.
Continue Reading: Benicar Settlement